Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a

Hepatology

Volumn 30, Issue 1, 1999, Pages 277-282

  Carreño, Vicente ^a   Marcellin, Patrick ^b   Hadziyannis, Stephanos ^c   Salmerón, Javier ^d   Diago, Moisés ^e   Kitis, Geoge E ^f   Vafiadis, Irene ^g   Schalm, Solko W ^h   Zahm, Friederike ⁱ   Manzarbeitia, Félix ^a   Javier Jimenez F ^a   Quiroga, Juan Antonio ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b BEAUJON HOSPITAL   (France)

^c HIPPOKRATION HOSPITAL   (Greece)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^f G PAPANICOLAOU HOSPITAL   (Greece)

^g LAIKO GENERAL HOSPITAL   (Greece)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; VIRUS DNA;

ABDOMINAL PAIN; ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG TOLERABILITY; ERADICATION THERAPY; FATIGUE; FEMALE; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; LIVER FIBROSIS; LIVER HISTOLOGY; LIVER NECROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETREATMENT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT FAILURE; TREATMENT PLANNING; VIRUS LOAD;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BIOPSY; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INFLAMMATION; INTERFERON ALFA-2A; LIVER; MALE; MIDDLE AGED; NECROSIS; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 0033000312     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300117     Document Type: Article

References (22)

1. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. HEPATOLOGY 1995;21:77-82.
2. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
3. Alexander GJ, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston AL, Williams R. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet 1987;ii:66-69.
4. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, et al. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
5. Carreńo V, Castillo I, Molina J, Porres JC, Bartolome J. Long-term follow-up of hepatitis B chronic carriers who responded to interferon therapy. J Hepatol 1992;15:102-106.
6. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Baker B, Korenman J, Bergasa NV, et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993;88:1887-1892.
7. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
8. Thomas HC, Lok ASF, Carreño V, Farrell G, Tanno H, Perez V, Dusheiko GM, et al. Comparative study of three doses of interferon alfa-2a in chronic active hepatitis B. The International Hepatitis Trial Group. J Viral Hepat 1994;1:139-148.
9. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-1427.
10. Lau DT, Everhart J, Kleiner DE, Park Y, Vergalla J, Schmid P, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997;113:1660-1667.
11. Janssen HLA, Schalm SW, Berk L, de Man RA, Heijtink RA. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B. J Hepatol 1993;17(Suppl 3):S47-S51.
12. Desmet VJ, Gerber MA, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. HEPATOLOGY 1994;19:1513-1520.
13. Janssen HLA, Berk L, Schalm SW, Heijtink RA, Hess G, Rossol S, Meyer zum Buschenfelde KH, et al. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B. Gut 1992;33:1094-1098.
14. Krogsgaard K, Christensen E, Bindslev N, Schalm S, Andersen PK, Ring-Larsen H. Relation between treatment efficacy and cumulative dose of alpha Interferon in chronic hepatitis B. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1996;25:795-802.
15. Kuhns MC, McNamara AL, Cabal CM, Decker RH, Thiers V, Brechet C, Tiollais P: A new assay for quantitative detection of hepatitis B viral DNA in human serum. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York, NY: Alan R. Liss Inc, 1988;258-262.
16. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
17. Bertoletti A, Costanzo A, Chisari FV, Levrero M, Artini M, Sette A, Penna A, et al. Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994;180:933-943.
18. Marines G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. HEPATOLOGY 1996;24:991-995.
19. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. HEPATOLOGY 1989;10:761-763.
20. Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993;105:1833-1838.
21. Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreño V, et al. The treatment effect of alpha Interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994;21:646-655.
22. Payne RJH, Nowak MA, Blumberg BS. The dynamics of hepatitis B virus infection. Proc Natl Acad Sci U S A 1996;93:6542-6546.